A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its ...
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...
6don MSN
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
6don MSN
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...
After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results